A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Liver metastases; Oropharyngeal cancer; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transgene
- 14 Oct 2024 Primary endpoint (Phase II part 2: Progression Free Survival (PFS) by RECISIT 1.1) has not been met, according to a Transgene media release.
- 14 Oct 2024 Top line results presented in a Transgene media release.
- 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.